At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 81 enrolled
Drug / intervention
eribulin mesylatedrug
Likely dose
eribulin mesylate 1.4mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Single-Arm, Feasibility Study of Dose Dense Doxorubicin and Cyclophosphamide (AC) Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer
In Brief
A Phase 2 clinical trial evaluating eribulin mesylate for HER2-normal. Completed, enrolled 81 participants across 2 sites.
Detailed Summary
The purpose of this study is to assess the feasibility of dose-dense doxorubicin and cyclophosphamide followed by eribulin mesylate for adjuvant treatment of early stage breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHER2-normal
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2011
First PostedApr 2011
Primary CompletionOct 2014
Study CompletionOct 2017
TodayJul 2026
First PostedApr 4, 2011
Enrollment StartMar 3, 2011
Primary CompletionOct 27, 2014
Study CompletionOct 19, 2017
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 15.2 years ago
Interventions
eribulin mesylatedrug
Dose dense doxorubicin and cyclophosphamide for 4 cycles during the first 8 weeks followed by eribulin mesylate 1.4mg/m2 for 4 cycles during the next 12 weeks.